Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
12,083 total articles
David V. Elkins, Executive Vice President and Chief Financial Officer of Bristol Myers Squibb (BMY), sold 30,000 shares of company stock on April 1, 2026, in two transactions totaling roughly $1.85 million. The trades were carried out under a pre-arranged Rule 10b5-1 plan put in place on June 3, 2025. The stock has risen sharply over six months and…
Daniel J. Sajkowski, a director at Calumet, Inc. /DE (NASDAQ: CLMT), sold 3,310 shares of common stock on April 1, 2026 under a Rule 10b5-1 trading plan, generating $114,062 at a weighted average price of $34.46. The transaction occurred while CLMT traded near its 52-week high. Separately, Calumet disclosed an unplanned maintenance outage at its Sh…
Edward Meyercord, president and CEO of Extreme Networks, sold 50,000 shares on April 1, 2026, for $765,185 and simultaneously exercised options to acquire 50,000 shares at $6.70. The company reported a second-quarter 2026 earnings beat and was flagged by Wolfe Research for high activist attractiveness; the stock has fallen 26% over the past six mon…
Twilio Inc. Chief Financial Officer Aidan Viggiano completed $1,010,653 in Class A share sales on March 31, 2026, via a series of sell-to-cover transactions mandated under the company’s equity incentive plan. The trades, disclosed on a Form 4 filing, reduced withholding obligations but do not reflect discretionary selling. Twilio’s stock trades abo…
Charles van Es, Chief Commercial Officer at The Vita Coco Company, Inc. (NASDAQ: COCO), sold 2,000 shares on April 1, 2026, for $97,340 under a Rule 10b5-1 plan. The transaction follows a 61% 12-month stock run and comes amid analyst price-target increases and a board appointment for retail executive Shelley Broader. Analysis tools cited in filings…
Marshall T. Reynolds, a director of First Guaranty Bancshares, Inc. (NASDAQ: FGBI), purchased 32,176 shares on March 31, 2026, for $7.77 per share, a $250,007 investment. The stock has since traded at $9.20, a 64% year-to-date rise. Reynolds' direct and indirect holdings are detailed, and the bank disclosed amendments to two loan agreements with Sm…
Lori A. Conkling, a director at Interactive Brokers Group, purchased 25 shares of Class A common stock on April 1, 2026, for $68.38 each, a total outlay of $1,709. The transaction leaves Conkling with 2,434 shares directly held. The move coincides with robust fourth-quarter 2025 financials, product expansions in crypto derivatives and Canadian reti…
Union Pacific EVP of Operations Eric J. Gehringer sold 1,999 shares of common stock on March 20, 2026, under a Rule 10b5-1 plan, generating about $469,625. The railroad's shares have since traded higher than the sale price. The company is managing several material corporate developments, including a $1.2 billion locomotive modernization agreement w…
Peter C. Farrell, a member of ResMed Inc.'s board, sold 2,000 shares on April 1, 2026, for $225.00 per share, realizing $450,000. The transaction was made under a Rule 10b5-1 trading plan adopted in August 2025. The company recently reported fiscal 2026 second-quarter results that beat EPS estimates and met revenue expectations, prompting a range o…
Horizon Kinetics Asset Management LLC, a roughly 10% holder of Texas Pacific Land Corp, bought a single share of TPL on April 1, 2026 at $454.04, bringing its direct stake to 3,461,343 shares. The move coincides with Texas Pacific Land's Q4 2025 results that slightly missed analyst estimates and a notable price-target increase by KeyBanc, which cit…
TTM Technologies director Thomas T. Edman sold 16,800 shares on April 1, 2026, at $100.23 per share under a 10b5-1 sales plan, generating proceeds of approximately $1.68 million. The move comes after a 360% stock gain over the past year, though the share price has since retraced to $97.03. The company also posted stronger-than-expected fourth-quart…
Murray Stahl, President and Co-Portfolio Manager of RENN Fund, Inc. (RCG), bought 1,134 shares on April 1, 2026, at $3.25 per share for a total of $3,685. The purchase occurred as RCG traded close to its 52-week high of $3.31 and after a six-month gain of 24%. Stahl's reported direct and indirect holdings remain extensive, though he disclaims benef…
Edgewise Therapeutics Chief Medical Officer Joanne M. Donovan sold 28,662 shares of common stock on April 1, 2026, for about $926,095 under a pre-arranged Rule 10b5-1 plan and concurrently exercised options to acquire the same number of shares at $7.08 each. The stock is trading near its 52-week high and appears overvalued versus InvestingPro's Fai…
Terrance Lane Wilson, senior vice president and general counsel of Williams Companies, sold 2,000 shares of the company's common stock on April 1, 2026, for $71.75 per share, realizing $143,500. The transaction was carried out under a 10b5-1 trading plan and leaves Wilson with 289,159 shares directly and 100 shares indirectly through a trust. Separ…
EOG Resources Executive Vice President and COO Jeffrey R. Leitzell executed a series of stock transactions on March 31, 2026, including an outright sale and multiple dispositions tied to the exercise of stock appreciation rights (SARs), while also acquiring shares through SAR exercises. The moves came as EOG reported mixed fourth-quarter 2025 resul…
Lynx1 Capital Management L.P., a roughly 10% holder of Korro Bio, Inc. (NASDAQ: KRRO), purchased 520 shares of common stock on March 31, 2026, at $10.60 per share for a total of $5,512. The company’s shares have since traded up to $13.85, a roughly 30% increase from the purchase price. Korro Bio has also announced an $85 million private equity fina…
Carnival director Sir Jonathon Band sold a total of 12,000 Carnival Corp (CCL) shares in two transactions that together amounted to $314,265. The trades occurred on March 31 and April 1, 2026. The company recently reported first-quarter 2026 results that modestly exceeded expectations on adjusted EBITDA and adjusted EPS, while analysts issued a ran…
Carnival Plc director Sir Jonathon Band sold 12,000 Trust Shares in two transactions on March 31 and April 1, 2026, realizing $314,265. The trades occurred at prices between $24.982 and $26.19, modestly above the stocks current quote of $25.65. After the disposals, Sir Jonathon Band holds 52,601.3359 Trust Shares directly. InvestingPro analysis cit…
On April 1, 2026, Lawrence T. Oliver, Senior Vice President and Secretary of RGC Resources Inc (RGCO), acquired 9.238 shares at $21.65, a transaction valued at roughly $200. The move comes while the utility's shares trade near a 52-week high and following a first-quarter report that missed EPS estimates but topped revenue expectations. The company …
RGC Resources Vice President of Human Resources Miles Christen Brooke purchased 4.619 shares of common stock on April 1, 2026, for a total of $100 under the company’s Dividend Reinvestment and Stock Purchase Plan. The company reported first-quarter fiscal 2026 earnings per share of $0.47, below analysts' $0.54 forecast, while revenue came in at $30…
William A. Richardson disposed of 20,000 shares of Gold.com, Inc. (NASDAQ:GOLD) on March 31, 2026, for $40.00 per share, realizing $800,000. The transaction occurred while the shares traded near $40.91, following a roughly 70% return over the prior 12 months. Gold.com finalized acquisition of the remaining 55.1% of Sunshine Minting, Inc., and annou…
Vicki L. Sato, a director at Vir Biotechnology, sold 22,000 shares on April 1, 2026 under a Rule 10b5-1 plan, generating $199,616 in proceeds. The transaction comes amid recent equity offerings and analyst price-target increases tied to a collaboration with Astellas Pharma; Vir's shares have returned 59% over the past six months.
A Tivic Health director purchased 19,000 shares on April 1, 2026, totaling $18,008, according to a Form 4 filing. The transaction occurs as the company transitions from consumer devices to a biopharmaceutical focus and secures funding for preclinical Entolimod studies aimed at protecting against lethal radiation exposure.
Princeton Bancorp director Stephen Shueh bought a total of 10,500 common shares in two transactions, bringing his direct stake to 42,038 shares. The purchases, totaling $297,395, occurred on May 15, 2023 and May 3, 2024. The company also announced a quarterly cash dividend of $0.35 per share payable February 27, 2026 to holders of record on Februar…
Scynexis INC Chief Executive Officer David Angulo Gonzalez purchased 108,695 shares at $0.92 per unit in a private placement on April 1, 2026, and received warrants for an equal number of shares. The move accompanies a planned roughly $40 million financing, recent clinical-stage milestones for SCY-247 and analyst price targets in the $3 to $4 range…
